TMOD2: A Potential Drug Target for Cancer (G29767)

Target Name: TMOD2

NCBI ID: G29767

TMOD2

TMOD2: A Potential Drug Target for Cancer

TMOD2 (Tumor Model of the Day 2), also known as TMOD2-ASA, is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and gastrointestinal tract. It is a key regulator of cell growth and differentiation, and has been implicated in the development and progression of many types of cancer.

TMOD2 is a tumor suppressor gene that has been shown to play a critical role in the development of various types of cancer, including neurobladder cancer, colorectal cancer, and gastric cancer. It is also has been shown to be involved in the development of leukemia and other blood cancers.

The TMOD2 gene has four splice variants, which are used to generate different forms of the TMOD2 protein. The most abundant form of TMOD2 is a protein called TMOD2-ASA, which is 21 kDa in size. TMOD2-ASA is a key regulator of cell growth and differentiation, and has been shown to play a role in the development and progression of many types of cancer.

The TMOD2 gene is located on chromosome 6p21.2 and has been implicated in the development of many types of cancer. It is a tumor suppressor gene that has been shown to play a critical role in the development and progression of cancer.

TMOD2 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also has been shown to be involved in the development of uveal cancer.

TMOD2 has also been shown to be involved in the development of skin diseases, such as melanoma and seborrheic cancer.

In addition to its role in cancer development, TMOD2 has also been shown to play a role in the regulation of normal cell function. It is a regulator of cell adhesion, which is the process by which cells stick together to form tissues and organs. It is also a regulator of cell migration, which is the process by which cells move from one location to another in the body.

TMOD2 has also been shown to play a role in the regulation of the immune system. It is a regulator of the T-cell receptor, which is the receptor that the immune system uses to detect and respond to foreign substances in the body.

TMOD2 has also been shown to play a role in the regulation of the cell cycle. It is a regulator of the G1 phase of the cell cycle, which is the stage of cell growth and division where DNA is replicated.

In conclusion, TMOD2 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell growth and differentiation, as well as the development and progression of many types of cancer. It is a tumor suppressor gene that has been implicated in the development and progression of many types of cancer, including neurobladder cancer, colorectal cancer, and gastric cancer. It is also has been shown to be involved in the development of leukemia and other blood cancers, as well as in the regulation of normal cell function and the immune system, and in the regulation of the cell cycle. Therefore, TMOD2 is a potential drug target and a biomarker for the diagnosis and treatment of various types of cancer.

Protein Name: Tropomodulin 2

Functions: Blocks the elongation and depolymerization of the actin filaments at the pointed end. The Tmod/TM complex contributes to the formation of the short actin protofilament, which in turn defines the geometry of the membrane skeleton (By similarity)

The "TMOD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMOD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets